Research Topics
| J N GeorgeSummaryAffiliation: University of Oklahoma Health Sciences Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancyJ R McMinn
Hematology-Oncology Section, Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
J Clin Apher 16:202-9. 2001..This review addresses the evaluation and management of these syndromes and describes a clinical approach for determining when plasma exchange is appropriate...- Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. American Society of HematologyJ N George
Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA
Ann Med 30:38-44. 1998..This review describes the principle features of ITP in children and adults, the process of development of the practice guideline for ITP, and the implications of the guideline for the diagnosis and management of patients with ITP... - The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndromeJames N George
The University of Oklahoma Health Sciences Center, Hematology Oncology Section, PO Box 26901, Oklahoma City, OK 73190, USA
Curr Opin Hematol 10:339-44. 2003.... - Idiopathic thrombocytopenic purpura: current issues for pathogenesis, diagnosis, and management in children and adultsJames N George
Hematology Oncology Section, The University of Oklahoma Health Sciences Center, PO Box 26901, Oklahoma City, OK 73190, USA
Curr Hematol Rep 2:381-7. 2003..Because major bleeding in ITP is rare, physicians must be certain that the adverse effects of treatment are not worse than the risks of bleeding caused by ITP... - Thrombotic thrombocytopenic purpura: a syndrome that keeps evolvingJames N George
Hematology-Oncology Section, Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA
J Clin Apher 19:63-5. 2004 - Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: diagnosis and treatmentJ N George
Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA
Cleve Clin J Med 68:857-8, 860, 863-4 passim. 2001..Nevertheless, death and long-term complications remain common. The recent relaxation of diagnostic criteria has dramatically increased the number of patients treated for clinically suspected TTP-HUS... - Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine careJames N George
Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA
Am J Hematol 74:161-9. 2003..However, compliance with this anti-D regimen was not feasible for many patients and/or their physicians... - How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndromeJ N George
Hematology Oncology Section, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
Blood 96:1223-9. 2000..Multipractice clinical trials are required to define optimal management. (Blood. 2000;96:1223-1229).. - PlateletsJ N George
Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA
Lancet 355:1531-9. 2000..Thrombocytopenia and disorders of platelet function cause petechiae and mucocutaneous bleeding. Drugs causing specific inhibition of platelet function are important in the treatment of cardiovascular and cerebrovascular disease... - Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: diagnosis and managementJ N George
Oklahoma Blood Institute, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA
J Clin Apher 13:120-5. 1998..This review describes the evolution of the syndrome of TTP-HUS in the current era of effective treatment, and describes the management and clinical outcomes among patients treated by the Oklahoma Blood Institute... - Idiopathic thrombocytopenic purpura: diagnosis and managementJ N George
Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA
Am J Med Sci 316:87-93. 1998..This review describes the clinical features of ITP in adults, emphasizes the principal unresolved issues in diagnosis and management, and outlines the critical areas for future research... - Unintentional platelet removal by plasmapheresisJ J Perdue
Hematology-Oncology Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA
J Clin Apher 16:55-60. 2001..40, P = 0.011). In these 39 patients, the platelet counts were significantly decreased at 24 hours (P = 0.002)... - Occult quinine-induced thrombocytopeniaK Kojouri
College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, USA
J Okla State Med Assoc 93:519-21. 2000..The diagnosis thrombocytopenia caused by common drugs can be difficult, requiring persistent, explicit questions... - The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUSJames N George
Department of Medicine, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, 73190, USA
Semin Hematol 41:60-7. 2004..Prospective data from consecutive patients are essential to translate new observations on pathogenesis into improved patient care... - ADAMTS13, thrombotic thrombocytopenic purpura, and hemolytic uremic syndromeJames N George
The University of Oklahoma Health Sciences Center, PO Box 26901, Oklahoma City, OK 73190, USA
Curr Hematol Rep 4:167-9. 2005 - The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiencyD R Terrell
Hematology-Oncology Section, Department of Medicine, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
J Thromb Haemost 3:1432-6. 2005..The greater incidence among women and blacks is comparable with their increased risk for other autoimmune disorders... - Idiopathic thrombocytopenic purpura in adults: current issues for pathogenesis, diagnosis and managementJames N George
University of Oklahoma Health Sciences Center, Oklahoma City, USA
Hematol J 5:S12-4. 2004 - Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomesV Roy
Hematology-Oncology Section, Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
Bone Marrow Transplant 27:641-6. 2001..3) Urgent intervention with plasma exchange when TTP is suspected following BMT may not always be appropriate. Alternative explanations for the signs and symptoms should be considered and treated aggressively... 
Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparisonCharity A Karpac
College of Public Health, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
Br J Haematol 141:696-707. 2008..05 for all differences). Awareness of the continuous occurrence of sporadic bloody diarrhoea-associated TTP-HUS in adults is important for prompt diagnosis and appropriate management...- Management of patients with refractory immune thrombocytopenic purpuraJ N George
Hematology Oncology Section, Department of Biostatistics and Epidemiology, Colleges of Medicine and Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
J Thromb Haemost 4:1664-72. 2006..In preliminary reports, these agents have been effective in maintaining safe platelet counts in patients with chronic ITP that was refractory to splenectomy and other treatments... - Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndromeP J Medina
Department of Pharmacy, Clinical and Administrative Sciences, College of Pharmacy and Hematology Oncology Section, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma 73190, USA
Curr Opin Hematol 8:286-93. 2001..Recognition of a drug-associated etiology in a patient with TTP-HUS is critical to avoid re-exposure and recurrent illness... - Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemmaJames N George
Department of Medicine, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA
Transfusion 44:294-304. 2004..Nevertheless, because multiple transplant-related sequela can cause the characteristic clinical features of TTP-HUS, the diagnosis is difficult... - The role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromeJames N George
The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
Clin Adv Hematol Oncol 3:627-32. 2005..This interpretation is consistent with other vascular and thrombotic disorders in which multiple risk factors and associated conditions contribute to the etiology of acute events... - For low platelets, how low is dangerous?James N George
Hematology Oncology Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA
Cleve Clin J Med 71:277-8. 2004 - Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantationRammurti T Kamble
Oklahoma University Health Sciences Center, Oklahoma City, Oklahama 73190, USA
Biol Blood Marrow Transplant 12:506-10. 2006.... - Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disordersJames N George
Hematology Oncology Section, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, 73190, USA
J Clin Apher 21:49-56. 2006..These observations from small uncontrolled case series provide the background and rationale for a randomized clinical trial to establish the role of rituximab in the management of patients with TTP... - Clinical practice. Thrombotic thrombocytopenic purpuraJames N George
Hematology-Oncology Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, USA
N Engl J Med 354:1927-35. 2006 - Tibor Greenwalt Award. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: a program for patient care, education and researchJames N George
Hematology Oncology Section, Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
Transfusion 44:1384-92. 2004..The Oklahoma TTP-HUS Registry provides educational and research opportunities, in addition to improved patient care, and serves as a model for productive collaboration of community blood centers and universities... - Recent advances in the treatment of chronic refractory immune thrombocytopenic purpuraKiarash Kojouri
Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA
Int J Hematol 81:119-25. 2005..An alternative approach, the stimulation of platelet production with thrombopoietic agents, has been successful in investigational studies and may provide a new management option... - Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published casesKristin K Francis
Hematology Oncology Section, Department of Medicine, The University of Oklahoma Health Sciences Center, Room CHB 358, PO Box 26901, Oklahoma City, Oklahoma 73190, USA
Oncologist 12:11-9. 2007.... - Evaluation and management of patients with thrombotic thrombocytopenic purpuraJames N George
Hematology Oncology Section, College of Medicine, Department of Biostatistics and Epidemiology, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
J Intensive Care Med 22:82-91. 2007..The continuing mortality from TTP, the risks of plasma exchange treatment, and the potential for recurrent episodes of TTP are clinical challenges that remain to be solved... 
Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromesDeirdra R Terrell
Department of Biostatistics and Epidemiology, College of Public Health, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73126 0901, USA
Am J Hematol 85:844-7. 2010..These observations of different gender and race disparities among the TTP-HUS syndromes suggest the presence of different risk factors and may serve as starting points for novel investigations of pathogenesis...- The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reportsDeirdra R Terrell
Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, 73126 0901, USA
Am J Hematol 85:174-80. 2010..3 per 10(5) adults/year. An important limitation of these studies is that they are primarily from Europe and may not be generalizable to all regions... - Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpuraSpero R Cataland
Department of Medicine, Columbus, OH, USA
Eur J Haematol 83:559-64. 2009..We studied the clinical utility of demographic and ADAMTS13 biomarker data to predict the risk for exacerbation... - Lessons learned from the Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registryJames N George
College of Public Health, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73126 0901, USA
J Clin Apher 23:129-37. 2008.... - ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patientsSara K Vesely
Hematology-Oncology Section, The University of Oklahoma Health Sciences Center, PO Box 26901, Oklahoma City, OK 73190, USA
Blood 102:60-8. 2003..Therefore, severe ADAMTS13 deficiency does not detect all patients who may be appropriately diagnosed with TTP-HUS and who may respond to plasma exchange treatment... - Congenital thrombotic thrombocytopenic purpura: Lessons for recognition and management of rare syndromesJames N George
Colleges of Public Health and Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
Pediatr Blood Cancer 50:947-8. 2008 - Treatment of drug-induced thrombocytopeniaStacey D Zondor
College of Pharmacy, Department of Pharmacy, University of Oklahoma Health Sciences Center, 1110 North Stonewall, Post Office Box 26901, Oklahoma City, OK 73190 5040, USA
Expert Opin Drug Saf 1:173-80. 2002.... - The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: the Swiss connectionJames N George
Colleges of Public Health, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Eur J Haematol 80:277-86. 2008..With effective treatment it is more frequently diagnosed, the clinical presentations are more diverse, and long-term sequelae are becoming recognized... - Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosusJames N George
Hematology-Oncology Section, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA
South Med J 100:512-4. 2007 - Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trialsJames N George
Colleges of Medicine and Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73126 0901, USA
Br J Haematol 144:409-15. 2009..These results suggest that adult patients with chronic ITP have improved HRQoL following romiplostim therapy... - Clinical insights from observations on ADAMTS13 deficiency in liver cirrhosisJames N George
College of Public Health and Medicine, The University of Oklahoma Health Sciences Center, Hematology-Oncology Section, Oklahoma City, OK 73126-0901, USA
Thromb Haemost 99:987-8. 2008 - How I treat patients with thrombotic thrombocytopenic purpura: 2010James N George
Department of Biostatistics and Epidemiology, College of Public Health, Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Blood 116:4060-9. 2010..Although recovery may appear to be complete, many patients have persistent minor cognitive abnormalities. More effective as well as safer treatment for TTP is needed... - Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomesK Kojouri
Hematology-Oncology Section, Department of Medicine, University of Oklahoma Health Sciences Center, Box 26901, Oklahoma City, OK 73190, USA
Ann Intern Med 135:1047-51. 2001..If recurrent disease is to be prevented, clinicians must recognize quinine as a possible cause... - Initial management of adults with idiopathic (immune) thrombocytopenic purpuraJ N George
Hematology Oncology Section, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
Blood Rev 16:37-8. 2002..The use of WinRho may also reveal the occurrence of spontaneous remissions, a previously unrecognized subgroup of adults with chronic ITP... - Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reportsKaren K Swisher
Hematology Oncology Section, Department of Medicine, College of Medicine, The University of Oklahoma Health Science Center, Oklahoma City, OK 73190, USA
Haematologica 92:936-43. 2007..We describe the occurrence of TTP-HUS following pancreatitis and consider whether pancreatitis may be a triggering event for acute episodes of TTP-HUS... - Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpuraQurana F Lewis
Department of Biostatistics and Epidemiology, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
Transfusion 49:118-24. 2009..After recovery from thrombotic thrombocytopenic purpura (TTP), patients commonly describe persistent problems with memory, concentration, and endurance... - Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndromeSara K Vesely
Hematology-Oncology Section, Department of Medicine, College of Medicine, The University of Oklahoma Health Science Center, Oklahoma City, Oklahoma
Transfusion 44:1149-58. 2004..CONCLUSIONS: Although pregnancies in these women were often complicated, a future pregnancy may be a safe and appropriate decision for women who have recovered from TTP-HUS... - The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: a community serviceKristina K Johnson
Department of Biostatistics and Epidemiology, College of Public Health, OUHSC, Oklahoma City, OK 73190, USA
J Okla State Med Assoc 100:273-8. 2007..Registry data are an important source of information for physicians and their patients, providing a complete community perspective of these uncommon disorders... - Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectivesJacqueline A Guidry
Department of Biostatistics and Epidemiology, College of Public Health University of Oklahoma Health Sciences Center, Oklahoma City, OK 73126 0901, USA
Eur J Haematol 83:175-82. 2009..We hypothesized that patients with ITP may have more concern about corticosteroid side-effects and less concern about serious bleeding than hematologists... - Thrombotic microangiopathy following allogeneic hematopoietic stem cell transplantationKiarash Kojouri
Hematology Oncology Section, Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
Curr Opin Oncol 19:148-54. 2007..The aim of this article is to assess the current understanding and uncertainties about the evaluation and management of thrombotic microangiopathy that occurs following allogeneic hematopoietic stem cell transplantation... - Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpuraKaren K Swisher
Hematology Oncology Section, Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
Transfusion 49:873-87. 2009..Reports of deterioration and death after platelet (PLT) transfusions in patients with thrombotic thrombocytopenic purpura (TTP) have led to recommendations that they should not be given except for life-threatening hemorrhage... - Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic reviewSara K Vesely
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA
Ann Intern Med 140:112-20. 2004..Potentially effective treatments must be evaluated by randomized, controlled trials to determine both benefit and safety... - Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006Loan Nguyen
Department of Biostatistics and Epidemiology, College of Public Health, The University of Oklahoma Health Science Center, Oklahoma City, OK 73190, USA
Transfusion 48:349-57. 2008..Twice-daily plasma exchange has been used for patients with thrombotic thrombocytopenic purpura (TTP) who are unresponsive to treatment with daily plasma exchange for many years but with no clear evidence of effectiveness... - Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methodsJessica A Reese
Department of Biostatistics and Epidemiology, College of Public Health, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
Blood 116:2127-33. 2010..Multiple methods, each with a distinct perspective, can contribute to the identification of drugs that can cause thrombocytopenia... - Endemic Esherichia coil O157:H7 infections and hemolytic-uremic syndrome in Oklahoma, 2002-2005Charity A Karpac
Department of Health Administration and Policy, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA
J Okla State Med Assoc 100:429-33. 2007..Although interpretation is limited by the few reports to OSDH, our data suggest that E. coli O157:H7 infections and HUS, presumably related to contaminated food, are endemic throughout Oklahoma... - Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy studyKoushan Siami
Department of Pathology, University of Oklahoma Health Sciences Center, 940 Stanton L Young Blvd, Oklahoma City, OK 73190, USA
Transplantation 85:22-8. 2008..The aims of this autopsy study were to determine the correlation between clinical and pathologic diagnosis of PTMA, to define the precise morphologic spectrum of PTMA, and to seek for potential etiologic factors... - A support group for patients who have recovered from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): The six-year experience of the Oklahoma TTP-HUS Study GroupMark A Howard
Hematology-Oncology Section, Department of Medicine, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA
J Clin Apher 18:16-20. 2003..The experience of The Oklahoma TTP-HUS Study Group suggests that it serves a previously unmet need... - Self-reported initial management of childhood idiopathic thrombocytopenic purpura: results of a survey of members of the American Society of Pediatric Hematology/Oncology, 2001Sara K Vesely
Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, USA
J Pediatr Hematol Oncol 25:130-3. 2003..This information provides the basis for designing a randomized clinical trial to compare the effect of different management strategies on the outcomes of bleeding symptoms, side effects of therapy, costs, and quality of life... - Salmonella sepsis caused by a platelet transfusion from a donor with a pet snakeMehrdad Jafari
Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA
N Engl J Med 347:1075-8. 2002 - Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpuraMelody Benjamin
Department of Medicine, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73126 0901, USA
Clin Infect Dis 48:1129-37. 2009..Case series of patients with a diagnosis of thrombotic thrombocytopenic purpura (TTP) have reported different frequencies of human immunodeficiency virus (HIV) infection; some series suggest that HIV infection may cause TTP... - Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complicationsKiarash Kojouri
Hematology-Oncology Section, Department of Medicine, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, USA
Blood 104:2623-34. 2004..6% (88 of 921 patients) with laparoscopic splenectomy. Although the risk of surgery is an important consideration, splenectomy provides a high frequency of durable responses for adult patients with ITP... - Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic reviewBeau M Hawkins
Department of Medicine, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
Transfusion 48:382-92. 2008..Autopsy studies consistently demonstrate cardiac involvement in thrombotic thrombocytopenic purpura (TTP), but clinical evidence for cardiac abnormalities is rarely reported... - Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanerceptJ R McMinn
Hematology-Oncology Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA
Am J Hematol 73:135-40. 2003..On the basis of these case reports, a clinical trial has been initiated to systematically evaluate the efficacy and risks of etanercept in the management of children and adults with chronic ITP... - Thrombocytopenia as an adverse effect of complementary and alternative medicines, herbal remedies, nutritional supplements, foods, and beveragesDerek J Royer
Department of Biostatistics and Epidemiology, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
Eur J Haematol 84:421-9. 2010.... - Cognitive deficits after recovery from thrombotic thrombocytopenic purpuraApril S Kennedy
Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73126 0901, USA
Transfusion 49:1092-101. 2009..Patients with apparent complete recovery from thrombotic thrombocytopenic purpura (TTP) often complain of problems with memory, concentration, and fatigue... - Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activitySpero R Cataland
Division of Hematology Oncology, Department of Internal Medicine, Ohio State University, Columbus, OH 43210, USA
Br J Haematol 139:486-93. 2007..These data suggest that the efficacy of CSA is at least in part related to its suppression of the antibody inhibitor of ADAMTS13 and a subsequent improvement in ADAMTS13 activity and antigen... - An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpuraSpero R Cataland
Division of Hematology Oncology, Department of Internal Medicine, Ohio State University, Columbus, OH 43210, USA
Br J Haematol 136:146-9. 2007..042). These data suggest that cyclosporin may have advantages over corticosteroids as an adjunct to PE therapy in the initial treatment of idiopathic TTP... - Bilateral nephrectomy for treatment resistant systemic lupus erythematosis and thrombotic thrombocytopenic purpura: a case reportMichael Feldman
Am J Hematol 82:496-7. 2007 - Thrombotic thrombocytopenic purpura: from the bench to the bedside, but not yet to the communityJames N George
Ann Intern Med 138:152-3. 2003 - Idiopathic thrombocytopenic purpura and myelodysplastic syndrome: distinct entities or overlapping syndromes?James N George
Leuk Res 26:789-90. 2002 - Thrombotic thrombocytopenic purpura: 2008 updateMark A Crowther
Division of Hematology, McMaster University, Hamilton, Ontario, Canada
Cleve Clin J Med 75:369-75. 2008..Unless TTP is recognized promptly and treated aggressively, most patients die of it... - Complications of plasma exchange in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a study of 78 additional patientsJ R McMinn
Transfusion 43:415-6. 2003 - Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndromeMark A Howard
Transfusion 46:154-6. 2006 - Thrombotic thrombocytopenic purpura: advances in pathophysiology, diagnosis, and treatment--introductionBernhard Lammle
Central Hematology Laboratory, Inselspital, University of Bern, Switzerland
Semin Hematol 41:1-3. 2004 - Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent diseaseBernhard Lammle
Haematologica 93:172-7. 2008 - Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trialDavid J Kuter
Massachusetts General Hospital, Boston, MA 02114, USA
Lancet 371:395-403. 2008..We assessed the long-term administration of romiplostim in splenectomised and non-splenectomised patients with ITP... - Immune thrombocytopenic purpura--let the treatment fit the patientJames N George
N Engl J Med 349:903-5. 2003 - A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trialSusan D Mathias
Ovation Research Group, San Francisco, CA 94105, USA
Clin Ther 29:950-62. 2007..A previous study reported preliminary evidence of its reliability and validity... - Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countriesJared R Adams
Department of Veterans Affairs, the MidWest Center for Health Services and Policy Research and the Veterans Affairs Chicago Healthcare System/Lakeside Division, Chicago, Illinois, USA
Am J Med 116:28-34. 2004..01). CONCLUSION: Financial considerations and a hemoglobin level <10 g/dL appear to influence erythropoietin use in the United States, whereas financial considerations alone determine erythropoietin use abroad... - How can we provide the best care for our patients with immune thrombocytopenic pupura?James N George
Mayo Clin Proc 79:456-7. 2004 - The child with immune thrombocytopenic purpura: is pharmacotherapy or watchful waiting the best initial management? A panel discussion from the 2002 meeting of the American Society of Pediatric Hematology/OncologyPaula Bolton-Maggs
Royal Liverpool Children s Hospital, Liverpool, UK
J Pediatr Hematol Oncol 26:146-51. 2004..The panel, composed of experts on both sides of the debate, presented the rationale, benefits, and risks of both pharmacotherapy and the watchful waiting strategy... - AMG 531, a thrombopoiesis-stimulating protein, for chronic ITPJames B Bussel
New York Presbyterian Hospital, New York, USA
N Engl J Med 355:1672-81. 2006..Most current treatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platelet destruction. In a phase 1-2 study, we administered a thrombopoiesis-stimulating protein, AMG 531, to patients with ITP... - Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working GroupTapani Ruutu
Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
Haematologica 92:95-100. 2007..An International Working Group was formed to develop a consensus formulation of criteria for diagnosing clinically significant TAM... - Drug-induced thrombocytopenia: an updated systematic review, 2006Xiaoning Li
Drug Saf 30:185-6. 2007 - Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspectiveSusan D Mathias
Health Outcomes Solutions, P, O, Box 2343 Winter Park, Florida 32790, USA
Health Qual Life Outcomes 6:13. 2008..The aim of this research is to develop a conceptual model to describe the impact of ITP and its treatment on patients' health-related quality of life (HRQoL)... 
A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validationSusan D Mathias
Ovation Research Group, 188 Embarcadero, San Francisco, CA 94105, USA
Health Qual Life Outcomes 5:11. 2007..Therefore, we sought to develop and validate the ITP-Patient Assessment Questionnaire (ITP-PAQ) for adult subjects with ITP...